API Holdings Consolidates 51% Stake in Thyrocare Technologies

API Holdings Limited has acquired 8,12,00,000 equity shares (51.02%) in Thyrocare Technologies Limited.
The transition follows an NCLT-approved scheme of amalgamation effective September 3, 2026.

Reader Takeaway: This internal restructuring consolidates control under API Holdings without altering the aggregate promoter group stake.

What just happened

Following the NCLT Mumbai Bench approval granted on August 31, 2026, the Scheme of Amalgamation between Docon Technologies Private Limited and API Holdings Limited has officially taken effect. As a result, the entire 51.02% stake previously held by Docon Technologies in Thyrocare Technologies has been legally vested into API Holdings.

Why this matters

The move represents a significant consolidation of shareholding within the promoter ecosystem. For shareholders, this signifies a streamlining of ownership structures where the parent entity, API Holdings, now directly holds the controlling interest previously parked under a subsidiary, Docon Technologies.

Promoter Group Context

Thyrocare Technologies has clarified that there is no change in the total shareholding of the Promoter and Promoter Group. This event is classified as an internal reorganization rather than a market-based acquisition or divestment.

Regulatory and Compliance

The company has filed the necessary disclosures under Regulation 29(1) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Necessary documentation has been submitted to the Registrar of Companies (RoC) as per the statutory requirements post-NCLT approval.